Latest Regulatory Reviews News

Page 1 of 16
Tuas subsidiary Simba Telecom has acknowledged unauthorised use of multiple Singapore spectrum bands, 5G indoor equipment and a breach of a document production order. The regulatory response now includes proposed board changes, but IMDA has yet to make or confirm findings.
Sophie Babbage
Sophie Babbage
17 Nov 2026
Heartland Group has pushed the expected completion of its proposed TSB Bank acquisition and merger with Heartland Bank to 1 March 2027. The revised date reflects outstanding Reserve Bank of New Zealand assessments and a TSB Section 95 review.
Claire Turing
Claire Turing
12 Nov 2026
Audalia Resources has lodged the key development and closure proposal for its Medcalf titanium-vanadium-iron project in Western Australia. The milestone advances the permitting process, but construction, financing and production remain dependent on further approvals and a final investment decision.
Maxwell Dee
Maxwell Dee
11 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
Westpac’s statutory FY26 profit fell 1% to $6.8 billion, while lending, deposits and underlying operating earnings moved higher. The bank maintained its fully franked final dividend at 77 cents per share, but rising impairment charges and margin pressure remain important counterweights.
Victor Sage
Victor Sage
2 Nov 2026
Raiz Invest delivered solid Q1 FY27 growth, with funds under management rising 20.2% to $2.40 billion and customer numbers reaching 354,202. But the fintech still cannot reliably quantify the potential impact of historical tax matters now under expert and regulatory review.
Claire Turing
Claire Turing
30 Oct 2026
Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.
Victor Sage
Victor Sage
30 Oct 2026
Australian Vanadium has moved its flagship project closer to an Optimised Feasibility Study while adding new industrial battery opportunities with Alcoa. But the September quarter also reduced cash to $12.4 million, leaving an estimated 2.5 quarters of funding at the reported spending rate.
Victor Sage
Victor Sage
30 Oct 2026
Richmond Vanadium Technology has submitted a revised preliminary environmental impact statement for its North Queensland vanadium project, setting up a possible public review in early 2027. The company ended September with A$3.49 million in cash and estimated funding for 2.6 quarters.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Alurion Resources has moved its Amargosa bauxite project into a field development program after completing its A$50 million IPO and ASX listing. Drilling, bulk sampling and logistics work are now feeding a direct-shipping-bauxite pre-feasibility study targeted for mid-2027.
Maxwell Dee
Maxwell Dee
27 Oct 2026
BLS Pharmaceuticals has started FY27 with its strongest quarter on record, reporting A$26.7 million in unaudited revenue and positive operating cash flow. The company reaffirmed its A$105 million to A$115 million revenue guidance while continuing to invest in Australian and Scottish manufacturing capacity.
Victor Sage
Victor Sage
21 Oct 2026
Wia Gold has emerged from a pivotal quarter with a 1.95Moz Probable Ore Reserve, A$229.2 million in cash and a proposed US$360 million debt facility supporting its Kokoseb development plan. Construction preparations are advancing, but lender approval, definitive financing documents and Namibian permits remain crucial hurdles before early works can begin.
Maxwell Dee
Maxwell Dee
20 Oct 2026

Browse the archive

Full archive